Know Cancer

or
forgot password

A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors


N/A
N/A
N/A
Open (Enrolling)
Both
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, Gastric Cancer (Inoperable and Recurrent)

Thank you

Trial Information

A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors


Inclusion Criteria:



- Small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer
and gastric cancer

- Patients with UGT1A1 genotype *1/*6, *1/*28, *6/*6, *28/*28 and *6/*28

- Patients to receiving CPT-11 plus platinum analogues (cisplatin, carboplatin and
nedaplatin) regimens (with or without molecular targeted agents)

Exclusion Criteria:

- Contraindication of CPT-11

- ECOG PS 3-4

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Influence of UGT1A1 genotypes on severe toxicities (ex. neutropenia) induced by CPT-11 based regimens

Outcome Time Frame:

3 or 6 months

Safety Issue:

Yes

Principal Investigator

Masashi Takano, MD. PhD.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Obstetrics and Gynecology, National Defense Medical College

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

TOP009-062

NCT ID:

NCT01040312

Start Date:

October 2009

Completion Date:

March 2014

Related Keywords:

  • Small Cell Lung Cancer
  • Non-Small Cell Lung Cancer
  • Cervical Cancer
  • Ovarian Cancer
  • Gastric Cancer (Inoperable and Recurrent)
  • UGT1A1, irinotecan
  • Carcinoma, Non-Small-Cell Lung
  • Uterine Cervical Neoplasms
  • Lung Neoplasms
  • Stomach Neoplasms
  • Ovarian Neoplasms
  • Small Cell Lung Carcinoma

Name

Location